“…MÉTODO: Estudo de coorte retrospectiva realizado por meio da análise de banco de dados do sistema de vigilância epidemiológica e vigilância ativa de IRAS de um hospital referência em tratamento de doentes infectados pelo Sars-Cov-2 na cidade de Goiânia, no período de um ano (01/04/2020 até 31/03/2021). …”
Enlace del recurso
Enlace del recurso

“…Four patients developed grade 1–2 immune related adverse events (irAE). Eight patients died because of cancer progression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MÉTODO: O estudo incluiu pacientes COVID-19 positivos (> 18 anos) associados com IRAS, hospitalizados entre abril a julho de 2020 e Março a Junho de 2021 em uma Unidade de Terapia Intensiva de 32 leitos. …”
Enlace del recurso
Enlace del recurso

“…ETHICS APPROVAL: NHS Research Ethics Committee 18/YH/0470 and IRAS-250981. TRIAL REGISTRATION: The trial was retrospectively registered at the International Standard Randomised Controlled Trial Number (ISRCTN) registry (registration date: 01/08/2022, registration number: ISRCTN10613839).…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Immune related adverse events (irAEs) are a management challenge with an associated increased morbidity and mortality. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study was reviewed and approved by London Brent Ethics Committee IRAS ID 204611 and received research governance approval from the sponsor, Sheffield Teaching Hospitals NHS Foundation Trust Research and Innovation Office STH19410.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTADOS: Observamos maior consumo de antimicrobianos de uso restrito nas UTIs (03 e 04/2021: DDD = 3.838 por 1.000 pcts/dia) e aumento da incidência de IRAS por MDR nos meses do aumento de internação por covid-19 (2,94 MDR por 1000 pcts/dia), principalmente nos meses de 03 e 04/2021. …”
Enlace del recurso
Enlace del recurso

“…INTRODUÇÃO/OBJETIVO: A pandemia COVID-19 favoreceu a disseminação de bactérias multirresistentes no ambiente hospitalar levando ao aumento das infecções relacionadas à assistência à saúde (IRAS) principalmente aquelas causadas por bactérias produtoras de carbapenemases. …”
Enlace del recurso
Enlace del recurso

“…A readequação dessas práticas é eficaz para o controle de surto e consequentemente redução das IRAS dentro de um serviço.…”
Enlace del recurso
Enlace del recurso

“…Overall, 21.0% (51/243) of patients in the experimental group experienced immune-related adverse events (irAEs), and all of these adverse effects were tolerated or remitted following drug treatment without affecting follow-up. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…ETHICS AND DISSEMINATION: This study is approved by the National Health Service South Central Research Ethics Committee (18/SC/0055); the UK Health Research Authority (IRAS ID 239091) and the UK Medicines and Healthcare products Regulatory Agency. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSÕES: É urgente avaliar o efeito de fatores de risco modificáveis para letalidade em pacientes submetidos à internações em UTI, como por exemplo a incidência de infecções relacionadas à assistência à saúde (IRAS). Para além de características individuais do hospedeiro e do vírus, tais fatores podem explicar a grande variabilidade nos desfechos de pacientes com COVID-19. …”
Enlace del recurso
Enlace del recurso

“…Foram consideradas as IRAS relacionadas a dispositivos invasivos (pneumonia, infecção urinária e infecção da corrente sanguínea), com cálculo da densidade de incidência (DI) por 1000 dispositivos-dia. …”
Enlace del recurso
Enlace del recurso

“…INTRODUÇÃO: Com a pandemia de COVID-19 o Serviço de Controle de Infecções Hospitalares (SCIH) além do desafio em lidar com os fluxos relacionados a COVID-19 e orientações de prevenção para pacientes e colaboradores, também enfrentou a disseminação de microrganismos multirresistentes causadoras de infecções relacionadas à assistência à saúde (IRAS). OBJETIVO: Avaliar o impacto das ações adotadas na redução de microrganismos multirresistentes (MDR) e no consumo de antimicrobianos (ATM) nas unidades de terapia intensiva (UTIs) durante a pandemia de COVID-19. …”
Enlace del recurso
Enlace del recurso

“…Secondary objectives will estimate the objective response rate (ORR), duration of response (DOR) progression free survival (PFS), progressive disease (PD) rate, and irAE rate of ipilimumab, nivolumab, and ciforadenant combination in untreated advanced RCC. …”
Enlace del recurso
Enlace del recurso

“…Reliable biomarkers are needed to better select the population that will benefit from ICB especially in older patients who may be at a higher risk of developing immune-related adverse events (irAEs) with a greater impact on their quality of life. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our experience managing 25 patients in our new Immune-Related Adverse Events (IRAE) clinic indicates that there are three distinct CIADM phenotypes. …”
Enlace del recurso
Enlace del recurso

“…In the real-world setting, no statistically significant differences in long-term outcomes with P vs PCT were observed; a prospective randomized trial addressing the comparative efficacy of P and PCT in different patient subgroups is highly anticipated.List of abbreviations: AE - adverse events; ALK - anaplastic lymphoma kinase gene; ALT - alanine aminotransferase; (a)NSCLC - (advanced) non-small cell lung cancer; AST - aspartate aminotransferase; BRAF - v-Raf murine sarcoma viral oncogene homolog B; BRCA2 - BReast CAncer gene 2; c-Met - tyrosine-protein kinase Met; CTCAE, v. 4.03 - Common Terminology Criteria for Adverse Events, version 4.03; CTLA-4 - cytotoxic T-lymphocyte-associated protein 4; ECOG PS - Eastern Cooperative Oncology Group performance status; EGFR - epidermal growth factor receptor gene; FISH - fluorescent in situ hybridization; HER2 - human epidermal growth factor receptor 2; IC - tumor-infiltrating immune cells; ICI - immune check-point inhibitors; IHC - immunohistochemistry; IQR - interquartile range; irAE - immune related adverse events; ISCORT - Israeli Society for Clinical Oncology and Radiotherapy; KRAS - Kirsten rat sarcoma viral oncogene homolog; (m)TTD -(median) time-to-treatment discontinuation; mo - months; (m)OS - (median) overall survival; (m)PFS - (median) progression-free survival; muts/Mb - mutations per megabase; NA - not specified/not available; NOS - not otherwise specified; NR - not reported/not reached; ORR - objective response rate; P - pembrolizumab; PCR - polymerase chain reaction; PCT - combination of pembrolizumab with platinum-based chemotherapy; PD – progression of disease; PD-1 - programmed cell death-1; PD-L1 - programmed cell death ligand-1; pts - patients; RET - proto-oncogene RET; ROS1 - proto-oncogene tyrosine-protein kinase ROS1; SD - standard deviation; STK11 - serine/threonine kinase 11; TC - tumor cells; TMB - Tumor mutation burden; TPS - tumor proportion score.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We have investigated the humoral and T-cell response of 39 patients with MDS two to four weeks following Covid-19 booster vaccination with BNT162b2 or ChAdOx1 nCoV-19 through the SOAP study (Sars-cov-2 fOr cAncer Patients, IRAS project ID:282337). Plasma and PBMCs from MDS cases and healthy controls have been collected, and are being assessed for both humoral and cellular responses to SARS_CoV_2, the alpha (B.1.1.7) and delta (B.1.617.2) variants. …”
Enlace del recurso
Enlace del recurso

“…CONCLUSION Identification of rare but serious irAEs like DKA, is very important. This requires a multi-dimensional approach involving effective education about the symptoms of DKA and hyperglycemia in patients receiving immunotherapy along with close monitoring of these patients. …”
Enlace del recurso
Enlace del recurso